Related Experiment Videos
Granulomatous hepatitis associated with glyburide
1Department of Pathology, New York Hospital Medical Center of Queens, Flushing, New York 11355, USA.
Digestive Diseases and Sciences
|February 1, 1996
Summary
Drug-induced granulomatous hepatitis can occur with sulfonylurea use. This case highlights a rare instance of granulomatous hepatitis linked to glyburide, a common diabetes medication, emphasizing the need for vigilance.
Area of Science:
- Hepatology
- Endocrinology
- Pharmacology
Background:
- Granulomatous hepatitis is a liver condition with diverse etiologies, including drug-induced forms.
- Sulfonylurea derivatives are widely used oral hypoglycemic agents for type 2 diabetes.
- Glyburide, a second-generation sulfonylurea, is generally considered to have fewer hepatic side effects compared to older agents like chlorpropamide.
Observation:
- A patient developed granulomatous hepatitis after approximately three years of glyburide therapy.
- This represents the second reported case of granulomatous hepatitis associated with glyburide.
- Previous reports have linked glyburide to cholestatic jaundice, hepatitis, and hypersensitivity vasculitis.
Findings:
- The presented case adds to the literature on glyburide-induced liver injury.
- The histological finding was necrotizing granuloma, a pattern observed in drug-induced liver disease.
- A review of existing literature was conducted to contextualize this case.
Implications:
- Physicians should consider glyburide as a potential cause of granulomatous hepatitis in patients with unexplained liver abnormalities.
- Further research may be warranted to fully elucidate the spectrum and incidence of hepatic side effects associated with glyburide.
- Early recognition and discontinuation of the offending agent are crucial for managing drug-induced liver injury.